

Terminal sterilization of oligonucleotide drug products

February 22 2023



Phosphate Buffer Screen, pH 7.5

The effect of formulation buffer on the stability of a model oligonucleotide during terminal sterilization at 115°C for 15 min. Credit: *Nucleic Acid Therapeutics* (2023). DOI: 10.1089/nat.2022.0073

A new report, coauthored by several major pharmaceutical companies, reviews the current state of sterile oligonucleotide drug product processing. The article, which provides recommendations to aid in the



evaluation and development of terminal sterilization processes, is published in *Nucleic Acid Therapeutics*.

All marketed oligonucleotide products are delivered as sterile preparations for parenteral delivery. The two most common methods for sterilizing parenteral drug products are terminal sterilization and membrane sterilization. Terminal sterilization provides greater sterility assurance than membrane sterilization, but not all drug products are amenable to terminal sterilization, which usually involves exposure to high heat or ionizing radiation.

Regarding the terminal sterilization of oligonucleotides, the authors provide recommendations for formulation development, assessing changes in the purity and impurity profile after terminal sterilization, and selecting the correct container closure.

"As the field continues to advance, commercial and <u>academic</u> <u>researchers</u> alike look to *Nucleic Acid Therapeutics* to provide the community with clear, detailed guidance on candidate therapeutic development and processing," says Executive Editor Graham C. Parker, Ph.D., Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.

More information: Daniel Paul DeCollibus et al, Considerations for the Terminal Sterilization of Oligonucleotide Drug Products, *Nucleic Acid Therapeutics* (2023). DOI: 10.1089/nat.2022.0073

Provided by Mary Ann Liebert, Inc

Citation: Terminal sterilization of oligonucleotide drug products (2023, February 22) retrieved 26 June 2024 from



https://medicalxpress.com/news/2023-02-terminal-sterilization-oligonucleotide-drug-products.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.